Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals is a global commercial-stage biotechnology company that develops innovative vaccines. Self-described to be committed to improving health worldwide.

Clover Biopharmaceuticals

Clover Biopharmaceuticals | 7,293 followers on LinkedIn. Unleashing the power of innovative vaccines to save lives and improve health around the world | Founded in 2007, we are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing, and commercial capabilities as well as strong partnerships with organizations globally, we have developed a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. As we focus on delivering vaccines for a healthier world, we remain steadfast in our dedication to both scientific innovation and equitable access.

Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals

Jeff Farrow

Senior Director Clinical Operation at Clover Biopharmaceuticals

Aurore Dujardin

Founder， Chairman of the Board of Clover Biopharmaceuticals

Peng Liang

Building Around Talent

Oscar Shen

Attend Europe’s Largest Vaccine R&D Conference！ ☘️☘️☘️ WE ARE ATTENDING AND PRESENTING! ☘️☘️☘️ 📍WORLD VACCINE CONGRESS MEET YOU THERE! #WVC #CLOVER #Vaccine #RSV

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-48.58M -	-912.90M 1,779.05%	-6.02B 559.03%	-2.45B 59.25%	-138.54M 94.35%
depreciation and amortization	2.40M -	5.78M 141.30%	25.39M 338.95%	60.09M 136.69%
deferred income tax			65.90M -
stock based compensation			125.21M -	95.02M 24.11%	53.52M 43.68%
change in working capital	18.57M -	751.51M 3,947.76%	1.08B 43.32%	56.63M 94.74%
accounts receivables
inventory	-393K -	-50.49M 12,746.82%	-771.65M 1,428.39%	-2.09B 170.90%
accounts payables
other working capital	18.96M -	802.00M 4,130.15%	1.85B 130.52%	2.15B 16.13%
other non cash items	1.00M -	632.53M 62,964.21%	3.80B 501.54%	549.34M 85.56%	85.02M 84.52%
net cash provided by operating activities	-26.62M -	476.93M 1,891.81%	-917.75M 292.43%	-1.69B 84.23%
investments in property plant and equipment	-6.82M -	-113.79M 1,569.48%	-80.32M 29.42%	-105.56M 31.43%
acquisitions net			21.06M -
purchases of investments		-280.33M -	-30M 89.30%	-13.93M 53.57%
sales maturities of investments			222.44M -	79.78M 64.13%
other investing activites	4.22M -		-21.06M -	2.20M 110.45%
net cash used for investing activites	-2.60M -	-394.12M 15,070.13%	112.12M 128.45%	-37.51M 133.45%
debt repayment	-1.73M -	-4.47M 159.10%	-14.73M 229.49%	-28.77M 95.27%
common stock issued		-327K -	1.75B 535,277.06%	453.15M 74.11%
common stock repurchased			-530.18M -
dividends paid			-100.59M -
other financing activites	143.78M -	321.65M 123.71%	1.95B 507.08%	58.76M 96.99%
net cash used provided by financing activities	142.05M -	316.85M 123.05%	3.06B 864.87%	483.14M 84.20%
effect of forex changes on cash	115K -	-32.16M 28,068.70%	-361K 98.88%	85.21M 23,703.88%
net change in cash	112.95M -	367.49M 225.36%	2.25B 512.58%	-1.16B 151.53%
cash at beginning of period	35.74M -	148.69M 316.00%	516.18M 247.15%	2.77B 436.12%	1.61B 41.92%
cash at end of period	148.69M -	516.18M 247.15%	2.77B 436.12%	1.61B 41.92%	1.61B 0%
operating cash flow	-26.62M -	476.93M 1,891.81%	-917.75M 292.43%	-1.69B 84.23%
capital expenditure	-6.82M -	-113.79M 1,569.48%	-80.32M 29.42%	-105.56M 31.43%
free cash flow	-33.43M -	363.13M 1,186.16%	-998.07M 374.85%	-1.80B 79.99%

2197

COM:CLOVERBIOPHARMA

Clover Biopharmaceuticals

Last Close

0.28

25/11 07:31

Market Cap

415.27M

Beta: -

Volume Today

313K

Avg: -

Preview